bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 1941: Barriers and effective interventions to engage Latinas' participation in breast cancer clinical trials
Authors: Padilla Monica J. , Karczmar Gregory 
Published: April 2023

Abstract
Breast cancer is the most diagnosed cancer among Latina women and is the leading cause of cancer-related death among Latinas (16.6%). While The Latino population is one of the fastest-growing populations in the US, they are severely underrepresented in clinical trials. Latinos make up 17% of the population but only 1% of clinical trial participants. Of clinical trials published covering 2001-2010, Latinos’ enrollment constituted only 2.2% of accrued participants. The percentage of Latino participants narrows down when we separate by gender. The goal of this study is to examine the prevalence of breast cancer-related barriers among Latinas and to determine the extent to which these barriers might influence Latinas enrolling in breast cancer clinical trials. If language and religion are the reason Latinas enroll less in breast cancer clinical trials, then increasing the availability of translated materials and a priest of a Catholic Church advertising the breast cancer studies will increase the enrollment rate of Latinas. Semi-constructed interviews were conducted with two Latino organizations to understand current barriers Latina’s face within the medical field. Based on these findings, I conducted an intervention at Our Lady of Tepeyac Church consisting of an information booth, making an announcement regarding Research Study 9127, and having bilingual Latinas available to give out more information while helping them enroll in Research Study 9127. At the end of the church intervention, 33 Latinas were enrolled in Research Study 9127, seeing a 550% increase in Latinas participating in Research Study 9127. Latinx women remain severely underrepresented in breast cancer clinical trials, thus limiting the generalizability of cancer clinical research, but interventions across churches would lead to improvements in general cancer knowledge, breast cancer screening practices, and intentions to enroll in clinical trials. This study can inform efforts to increase clinical trial participation in Latinas by highlighting important motivators to participation specific to Latinas and informing future interventions aimed at encouraging participation in clinical trials in a culturally sensitive and effective way.
Citation Format: Monica J. Padilla, Gregory Karczmar. Barriers and effective interventions to engage Latinas' participation in breast cancer clinical trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1941.
Abstract 1968: A multiomic spatial atlas of breast cancer in women of African ancestry
Authors: Plummer Jasmine T. , Nikulina Nadezhda , Omotoso Ayodele , Burnett Destiny , Coelho Priscilla , Badal Simone , Hurley Judith , Gomez Carmen , Ji Ha Yeun , Marcao Maycon , Segato Felipe Dezem , Braubach Oliver , George Sophia 
Published: April 2023

Abstract
The US Black population consists of both US-born Black and immigrant Black populations from the Caribbean and Africa. Normal tissues in Black individuals, independent of their country of birth or residence, are woefully understudied. Yet, Black individuals disproportionately develop aggressive pathologic diseases and are treatment refractory or resistant, thus leaing to premature deaths. In women, breast cancer is more common among US Black women, and the most common non-viral driven cancer in African and Caribbean countries. Furthermore, Black women develop this disease younger than other ancestral groups and have a higher incidence aggressive pathologies, such as metaplastic and triple-negative breast cancer. With the African-Caribbean Cancer Consortium (AC3) and Transatlantic Gynecologic Cancer Research Consortium, we have created a multiomic spatial atlas of triple-negative and other breast cancers across Africa, the Caribbean, and among US-Black individuals. We performed ultrahigh-plex RNA and protein spatial phenotyping on the PhenoCycler-Fusion (PCF). The PCF is a fast end-to-end spatial biology platform that enables whole-slide spatial readouts of RNA and protein moieties at single-cell resolution. Multiomic spatial phenotyping of tissues allowed for the detection of novel cell populations associated with a given African ancestry linking unique immune/stromal cell types to the outcome and severity of breast cancer. Here, we aim to develop a benchmark that confidently measures and interprets ancestral genomic differences at the cellular level. Deciphering the relationship between African ancestry, aggressive disease biology, and early onset will enable the characterization of the tissue composition and the proportion of cell sub-populations implicated in tumorigenesis and the interplay with germline genetics.
Citation Format: Jasmine T. Plummer, Nadezhda Nikulina, Ayodele Omotoso, Destiny Burnett, Priscilla Coelho, Simone Badal, Judith Hurley, Carmen Gomez, Ha Yeun Ji, Maycon Marcao, Felipe Dezem Segato, Oliver Braubach, Sophia George. A multiomic spatial atlas of breast cancer in women of African ancestry [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1968.
Abstract 1972: Potential predictors of prostate cancer screening: Findings from the MiCaP research digest study
Authors: Machuca Jessica Otero , Fathi Parisa , Lee Daniel , Walsh-Childers Kim , Odedina Folakemi 
Published: April 2023

Abstract
Introduction: Black men are disproportionately affected by prostate cancer (CaP) and havebeen found to experience more aggressive forms of cancer. The Minority Prostate Cancer(MiCaP) Research Digest is a dissemination platform with the goal of spreading community-based and culturally relevant ways to provide prostate cancer discoveries, interventions, andclinical trials among Black men. In collecting pretest data, the MiCaP team was also able tocollect data on whether participants had been tested for CaP in the last year. We were also ableto collect data on various social determinant variables to test for association.
Methods: Black men living in the United States ages 35 to 70 were recruited for this studythrough community-based methods. Participants were randomly assigned to an interventiongroup that received the MiCaP information material and a control group that watched a generalvideo. Both groups received baseline and follow-up surveys to assess their knowledge relatedto CaP clinical trials, testing, and treatment. Associations of characteristics from the baselinesurvey were evaluated using logistic regression models.
Results: A total of 220 responses are included in this dataset. The majority of participants wereborn in the United States (93.06%), single (49.52%), attended/graduated college (35.65%),between 60 and 69 years (25.58%), had full-time employment (52.07%), and had a householdincome between 20,000 and 39,999 (21.66%). Only about 35% had read or heard about clinicaltrials within the last year. Logistic regression found a positive association between the followingvariables and getting tested for prostate cancer in the past year: if participants had heard ofcurrent prostate cancer research or discoveries, if an immediate family member had beendiagnosed with prostate cancer, age, and level of education. No association was found betweeninsurance status, utilization of healthcare, clinical trial participation, or clinical trial knowledge.
Conclusion: There is an association between being aware of CaP discoveries, diagnosis of familymembers, education, and age with prostate cancer screening. Future work should be done tofurther explore this association and how to overcome the barriers those determinants mightprovide in screening. These data and future data on this can be used to further community-based interventions delivered in culturally relevant ways with the goal of encouraging positivehealth behaviors to reduce CaP in Black men.
Citation Format: Jessica Otero Machuca, Parisa Fathi, Daniel Lee, Kim Walsh-Childers, Folakemi Odedina. Potential predictors of prostate cancer screening: Findings from the MiCaP research digest study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1972.
Abstract 1982: Exploring the impact of metastatic breast cancer support group in Nigeria
Authors: Chidebe Runcie C. , Nwosu-Zitta Theodora , Orji Mary-Gloria A. , Banwo-Fatai Khadijat , Agha Agha A. , Esiaka Darlingtina K. , Orjiakor Tochukwu C. 
Published: April 2023

Abstract
Background: Over 70% of breast cancer patients in Nigeria present metastatic/advanced breast cancer (MBC). An estimated 90% of breast cancer deaths are as a result of metastatic disease, either at diagnosis or recurrence. MBC is associated with severe burden to the patient, family, healthcare delivery system and the society at large. Women living with MBC face many challenges ranging from poor access to MBC information, untreated pain, frequent break-down of radiotherapy machines and absence of peer support.
Method: In this research, we set up the first metastatic breast cancer support group in Abuja. The group meet once every month on a face-to-face basis and also uses WhatsApp group for regular meaningful engagement. We explored the impact of the group on the patient’s quality of life (QoL) using a focused group discussion (FGD). Eighteen (18) patients participated in the two sessions of FGD.
Result: Many of the patients report that the support group provides a culture of love and strength over their death anxiety, especially meeting other patients who have lived with MBC longer. They also report to have found peer support on the online WhatsApp group.
Citation Format: Runcie C. Chidebe, Theodora Nwosu-Zitta, Mary-Gloria A. Orji, Khadijat Banwo-Fatai, Agha A. Agha, Darlingtina K. Esiaka, Tochukwu C. Orjiakor. Exploring the impact of metastatic breast cancer support group in Nigeria [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1982.
Abstract 2046: Identification of the cuproptosis-related gene signature associated with the tumor environment and prognosis of patients with glioblastoma multiforme (GBM)
Authors: Ahmed Yaman B. , Al-Bzour Ayah N. , Al-Majali Ghayda'a N. , Khalefa Zaid M. , Alzghoul Saja M. 
Published: April 2023

Abstract
Background: Glioblastoma multiforme (GBM) is the most common tumor of the central nervous system with poor prognosis. Cuproptosis is a novel programmed cell death pathway targeting lipoylated tricarboxylic acid cycle proteins. Previous studies have found that it participates in tumor progression, but its role in GBM is still elusive. In this study, we aimed to develop a cuproptosis gene-signature risk score using bioinformatics analysis and machine learning.
Methods: We acquired transcriptomic and clinical information of GBM patients from The Cancer Genome Atlas (TCGA). A total of 2283 differentially expressed genes (DEGs) were obtained from the GEPIA2 database. 26 cuproptosis-related genes (CRGs) were retrieved from literature. A correlation analysis between the 26 CRGs and the DEGs were conducted to retrieve the cuproptosis-related DEGs. Then, a univariate cox analysis was conducted to obtain the prognostic-related DEGs for overall survival (OS). The least absolute shrinkage and selection operator (LASSO) were conducted for regularization and the gene risk score was constructed using the multivariate cox coefficients.
Results: A total of 731 downregulated DEGs were correlated with CRGs, while 68 upregulated DEGs were correlated with CRGs and were further screened for prognostic value using the univariate cox analysis. A total of 70 prognostic related CRGs were identified and were further screened using the LASSO cox analysis. After multivariate cox analysis, a total of seven genes were significantly associated with survival (p-value&lt;0.01). A risk-score gene signature was constructed from the cox coefficients multiplied by the expression of the following genes: -0.0012*DPP10+0.0021*EGR4+0.0015*ITPKA+ 0.0003* PTPRN+ 0.0007* STEAP2+ 0.0006* TENM2+- 0.0017* ZNF540.
Conclusion: Univariate and multivariate Cox regression analyses showed the CRGs-based prognostic signature independently functioned as a risk factor for OS in GBM patients. Furthermore, our results gave a promising understanding of cuproptosis in GBM, as well as a tailored prediction tool for prognosis and immunotherapeutic responses in patients.
Citation Format: Yaman B. Ahmed, Ayah N. Al-Bzour, Ghayda'a N. Al-Majali, Zaid M. Khalefa, Saja M. Alzghoul. Identification of the cuproptosis-related gene signature associated with the tumor environment and prognosis of patients with glioblastoma multiforme (GBM) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2046.
Abstract 2194: Performance of a 24-hour turnaround, guideline-complete NSCLC assay, optimized for sparse samples
Authors: Cabrera Kerri , Gole Jeff , Leatham Bryan , Regoli Isabel , Martinez Tiffany , Richards Andrew , Herdt Leah , Enciso Juan , Berroteran Paige , Carolan Heather , Brown Brad 
Published: April 2023

Abstract
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer with 236,740 new cases diagnosed in 2022 in the United States. In this study, we demonstrate the performance of a digital PCR (dPCR) based assay that reports 15 (NCCN) biomarkers using only 1 slide of FFPE tissue. ChromaCode’s High Definition PCR (HDPCR™) NSCLC Tumor Profiling Panel (Research Use Only) detects guideline biomarkers including variants for EGFR, BRAF, KRAS, ERBB2, ALK, ROS1, RET, MET, and NTRK1-3 with a 24 hour turnaround time and a simple PCR workflow. A total of 34 NSCLC FFPE specimens were evaluated using the HDPCR NSCLC Panel. DNA and RNA were extracted from a single 10 µm section of specimen, with a sister section previously characterized with the Oncomine Precision Assay GX. The DNA/RNA eluates (20ng DNA per well, 20ng RNA) were run with the HDPCR NSCLC Panel on the Qiagen QIAcuity dPCR instrument. Data analysis was conducted using ChromaCloud™, which includes a proprietary algorithm that can detect and quantify 6 targets (5 targets and 1 internal control) for each of the 3 wells. DNA samples discordant with the comparator assay were evaluated using the Archer DNA VariantPlex panel, while RNA discordant samples were analyzed using the Archer RNA fusion plex panel. Of the 34 specimens evaluated, 16 SNV, 13 Insertion/Deletion, and 7 fusion positive specimens were identified using NGS. On the dPCR assay, the results show a high-level of agreement, after discordant resolution, of 95.8% across the panel. The minor allele fraction (MAF), also calculated using ChromaCode Cloud, ranged from 5% to 90%. With 20 ng input (Qubit), the average copy number of amplifiable DNA ranged from 791 copies (~2.3 ng) to 6583 copies (~19.9 ng) with a mean of 2410 copies (~7.43 ng). Here we demonstrate that the HDPCR NSCLC Tumor Profiling Panel provides comparable performance to validated NGS assays with a turnaround that enables adherence to guideline-recommended treatment, and a low sample requirement that maximizes the number of patients for molecular testing. The standard protocols used by the assay and the use of a cloud based analysis pipeline enables easy deployment of this assay in any lab.
Citation Format: Kerri Cabrera, Jeff Gole, Bryan Leatham, Isabel Regoli, Tiffany Martinez, Andrew Richards, Leah Herdt, Juan Enciso, Paige Berroteran, Heather Carolan, Brad Brown. Performance of a 24-hour turnaround, guideline-complete NSCLC assay, optimized for sparse samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2194.
Abstract 2199: Novel urinary marker for diagnosis and prognosis of neuroblastoma
Authors: Hinoki Akinari , Amano Hizuru , Uchida Hiroo , Narita Atsushi , Kumano Shun , Abe Mayumi , Sakairi Minoru , Shirota Chiyoe , Sumida Wataru , Makita Satoshi , Takahashi Yoshiyuki , Osawa Tsuyoshi 
Published: April 2023

Abstract
Background and Aim: Urinary homovanillic acid (HVA) and vanillylmandelic acid (VMA) concentrations are widely used for diagnosis of neuroblastomas, which are catecholamine-secreting tumors. As recent advances in mass spectrometry have facilitated the measurement of metabolites present at extremely low concentrations, urinary metabolites with better diagnostic or prognostic utility for detection of neuroblastomas could be identified. This study utilized quantitative analyses using liquid chromatography-mass spectrometry (LC-MS) to evaluate the diagnostic and prognostic performance of a novel biomarker candidate: 3-methoxytyramine sulfate [3-MTS].
Materials and Methods: The concentrations of the three urinary metabolites (HVA, VMA, and 3-MTS) in urine samples of 41 patients with primary neuroblastoma and urine samples of 155 control participants were measured using LC-MS. The cut-off values for these metabolites were the mean + 2 standard deviation values of the control. Linear discriminant analysis was used to evaluate the association of urinary marker candidates with unfavorable risk factors such as the International Neuroblastoma Pathology Classification and MYCN amplification.
Results: The sensitivity and specificity were as follows: 3-MTS 90.2%, 94.2%; HVA 87.8%, 96.1%; VMA 87.8%, 96.1%; VMA or HVA+3-MTS 97.6%, 92.3%; HVA+VMA 87.8%, 94.8%; respectively. 3-MTS could differentiate between the cases with favorable and unfavorable histology (AUC =0.950). 3-MTS+VMA differentiated between the cases with MYCN amplification and nonamplification (AUC=0.952).
Conclusions: 3-MTS might be a useful urine marker for both diagnosis and prognosis of neuroblastoma.
Citation Format: Akinari Hinoki, Hizuru Amano, Hiroo Uchida, Atsushi Narita, Shun Kumano, Mayumi Abe, Minoru Sakairi, Chiyoe Shirota, Wataru Sumida, Satoshi Makita, Yoshiyuki Takahashi, Tsuyoshi Osawa. Novel urinary marker for diagnosis and prognosis of neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2199.
Abstract 2202: Role of FadA secreting Fusobacterium nucleatum in initiation and progression of colorectal cancer
Authors: Huang Angela , Saxena Anjana , Patel Mintoo 
Published: April 2023

Abstract
Colorectal cancer (CRC) is a global disease with poor prognosis. There is an alarming increase in incidence of CRC in younger patients along with well recognized racial disparities. Recent data implicate a role of microbiome in initiation and progression of CRC. Fusobacterium nucleatum (Fn), an oral opportunistic pathogen, has emerged as one of the common pathogens associated with CRC. Fn transformation from commensal to pathogen requires expression of amyloid-like FadA adhesin that plays a key role in its attachment to the colonic mucosal cells resulting in inflammatory, oncogenic, and metastatic changes. CRC initiates as polyps that go on to invade the mucosal layers and metastasize. This study analyzed the significance of Fn as a biomarker in CRC as well as to understand the etiology and metastasis of CRC. Deidentified and delinked formalin fixed paraffin embedded tissue sections from cancerous, precancerous and non-cancerous colorectal biopsies were analyzed for Fn presence and markers in epithelial to mesenchymal transition (EMT) in CRC through immunofluorescence. EMT was studied through biomarkers such as E-cadherin, which is an epithelial cell surface protein, vimentin as an intracellular filament protein normally expressed in mesenchymal cells, and N-cadherin, a cell adhesion molecule that is shown to express aberrantly in some solid tumor cells undergoing EMT. As expected, E-cadherin was abundantly expressed on the surface of epithelial cells while vimentin was found in the stromal cells in the non-cancerous tissue sections. Interestingly, the E-cadherin expression was lower in the cancerous tissue and some cancerous specimens also exhibited the vimentin positive foci within epithelial cells signifying partial EMT. N-cadherin expression was not observed in any of the specimens. The presence of Fn as analyzed through the FadA staining correlated with decline in the E-cadherin expression in some cancer specimens. To further analyze the significance of Fn, a meta-analytic study was conducted from 20 studies that indicated a significant presence of Fn not only in CRC tissues but also in fecal specimens from patients with CRC. A whole genome sequencing analysis corroborated with the abundance of Fn in CRC tissue specimens. These data suggest that analysis for Fn presence offers an attractive opportunity for intervention and targeted treatment for chemo resistant tumors. EMT analysis provides an additional corroboration in early detection of cancer progression which is pivotal in successful treatment of CRC.
Citation Format: Angela Huang, Anjana Saxena, Mintoo Patel. Role of FadA secreting Fusobacterium nucleatum in initiation and progression of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2202.
Abstract 2249: Development and validation of a pharmacodynamic (PD) assay for TOS-358, the first covalent inhibitor of PI3Kα in clinical development
Authors: MacDougall John R. , Mak Raymond , Bradley John , Simpson Allison , May Claire , Wei Lan , Ouellette Kendra , Olbrot Marty , Blair Jimmy , Dhawan Neil , Chen Wei 
Published: April 2023

Abstract
TOS-358 is a first-in-class covalent inhibitor of PI3Kα and is currently in clinical development in a variety of solid malignancies. We have developed a fit-for-purpose pharmacodynamic assay to evaluate the target occupancy of TOS-358 in in vitro and in vivo setting at multiple timepoints. The PI3Kα assay allows direct measurement of both occupied and total protein in multiple different samples and tissue types. Signals of occupied and unoccupied PI3Kα proteins can be readily measured in cellular and in vivo samples. The assay was utilized in a large panel of cancer cell lines, revealing a direct correlation between target occupancy and pathway inhibition of markers such as phosphoAKT and phosphoS6. Critically, these correlations revealed the need to achieve near complete suppression of PI3Kα to enable sustained pathway inhibition and cancer cell death. We furthermore utilized this assay to explore the turnover rate of PI3Kα across multiple diverse tumor types, mutations, and tissues. This approach enables highly sensitive target engagement analysis of TOS-358 across multiple formats.
Citation Format: John R. MacDougall, Raymond Mak, John Bradley, Allison Simpson, Claire May, Lan Wei, Kendra Ouellette, Marty Olbrot, Jimmy Blair, Neil Dhawan, Wei Chen. Development and validation of a pharmacodynamic (PD) assay for TOS-358, the first covalent inhibitor of PI3Kα in clinical development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2249.